Blood test may identify Alzheimer's risk years before symptoms emerge

Consumers may gain access to preventive health screening and lifestyle interventions, but face potential anxiety from false-positive results and increased healthcare costs. Early detection could reduce future out-of-pocket expenses for advanced dementia care, though screening costs and unnecessary treatments may increase near-term spending.

Governments must establish guidelines for appropriate use of blood biomarker testing to avoid unnecessary mass screening. Regulators need to balance early intervention benefits against false-positive risks. Healthcare systems should develop protocols for counseling asymptomatic individuals with positive biomarkers. Insurance coverage policies will need clarification regarding preventive screening and treatment eligibility.